HighMark Wealth Management LLC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H203. A total of 23 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
HighMark Wealth Management LLC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2022$4,000
-42.9%
6,9660.0%0.00%
-50.0%
Q2 2022$7,000
-30.0%
6,9660.0%0.01%
-14.3%
Q1 2022$10,000
-73.7%
6,9660.0%0.01%
-70.8%
Q4 2021$38,000
-5.0%
6,9660.0%0.02%
-17.2%
Q3 2021$40,0000.0%6,9660.0%0.03%0.0%
Q2 2021$40,000
+5.3%
6,9660.0%0.03%
-3.3%
Q1 2021$38,000
+18.8%
6,966
+4.5%
0.03%
+11.1%
Q4 2020$32,0006,6660.03%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Samjo Capital LLC 404,963$563,0000.48%
Cowen Prime Advisors LLC 332,197$462,0000.19%
ARMISTICE CAPITAL, LLC 834,054$1,159,0000.02%
Nantahala Capital Management 285,963$397,0000.02%
HighMark Wealth Management LLC 6,966$10,0000.01%
UBS Group AG 4,000$6,0000.00%
OSAIC HOLDINGS, INC. 13$00.00%
WELLS FARGO & COMPANY/MN 41$00.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GEODE CAPITAL MANAGEMENT, LLC 46,039$63,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders